Braftovi

Chemical Nameencorafenib
Dosage FormCapsule (oral; 75 mg)
Drug ClassKinase inhibitors
SystemSkin
CompanyArray Biopharma
Approval Year2018

Indication

  • Braftovi is indicated, in combination with binimetinib, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test.
Last updated on 10/19/2020

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Braftovi (encorafenib) Prescribing Information2019Array Biopharma
Document TitleYearSource
Systemic therapy for melanoma: ASCO guideline.2020American Society of Clinical Oncology